Taiwan+, Taiwan’s First English-language Video Platform Launched
Taiwan Plus (Taiwan+), the first English-language international streaming platform of Taiwan, was unveiled by Vice President Lai Ching-te, Legislative Speaker You Si-kun, Culture Minister Lee Yung-te, Central News Agency (CNA) Chairman Liu Ka-shiang, Taiwan+ CEO Joanne Tsai, and H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis at the National Taiwan Museum in Taipei on Aug. 30.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005461/en/
Taiwan's Vice President Lai Ching-te (center) waves to the audiences at the launch party of Taiwan+, the first English-language international streaming platform of the nation on Monday. The Central News Agency Chairman Liu Ka-shiang (from right), H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis in Taiwan, Culture Minister Lee Yung-te, Legislative Speaker You Si-kun, Taiwan+ CEO Joanne Tsai along with Taiwan+ News Center Director Divya Gopalan attended the event held at National Taiwan Museum. (Photo: Business Wire)
Targeting English-speaking audience, Taiwan+ consists of media professionals from the U.S., the U.K, Canada, France, and Australia, as well as local industry professionals, who work collaboratively to deliver the latest news about Taiwan, international affairs, and covers a wide range of topics. The platform also sources stories from Taiwan’s public and private media organizations.
Golden Melody-award winning singer Sanpuy Katatepan Mavaliyw opened the event with a music performance. Held with COVID-19 prevention measures in place, the event was joined by representatives including Izumi Hiroyasu from Japan, Jordan Reeves from Canada, Andrew Wylegala and Don Shapiro from the U.S., and Henry Chang and Giuseppe Izzo from Europe.
H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis in Taiwan said the international video platform is expected to connect Taiwan with the world.
President Tsai Ing-wen expressed her pleasure to join the launch of Taiwan+ with a video message, saying “Taiwan+ is an exciting new initiative to tell Taiwan’s story. Generations of Taiwanese fought to transform this country into a vibrant democracy that protects freedom of speech and expression.”
Premier Su Tseng-chang wished the platform success. He stressed that Taiwan is a democratic and free country guided by the rule of law, and cares about universal values of human rights, freedom of speech and diversity, noting that this is why many countries are willing to make friends and do business with Taiwan.
Vice President Lai said, “I hope that the platform can be the starting point from which the world learns about what Taiwanese people think and want, what Taiwan is doing, and what we can contribute to the world.”
Legislative Speaker You noted that, with China’s intimidation and political oppression against Taiwan, the establishment of Taiwan+ allows Taiwan to tell its stories to the world through its voices.
Taiwan+, a project commissioned by the Ministry of Culture to the CNA, marks an important milestone in the country’s history of mass media, Minister Lee said. He expressed his gratitude to legislators and professionals for making this happen.
“I hope to make this platform a form of expansion, connection, and infinite possibilities, just like how Taiwan incorporates ethnic, cultural and linguistic diversity, and introduce Taiwan to the world through dynamic storytelling and news,” said Tsai, a senior media professional with over 25 years of experience in international media outlets, such as NBC/CNBC, National Geographic, and Fox International Channels.
The content of Taiwan+ can be played on the Taiwan Plus app or viewed on its website and social media platforms, such as Facebook, YouTube, Twitter, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005461/en/
Contact information
Taiwan+
Hanna Liu 0988-653-078
hanna.liu@taiwanplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release
Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 03:00:00 EET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom